Companies PDS Biotechnology Corp
PDS Biotechnology (PDSB): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me PDS Biotechnology Corp’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,263,569FY2024
- $828,307FY2025
CEO total pay was $828,307 in fiscal 2025, down from $2,263,569 in fiscal 2024.
FY2025: salary $615,322 · bonus $0 · stock awards $0 · option awards $193,500
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Frank Bedu-Addo | $615,322 | $0 | $0 | $193,500 | $0 | $0 | $19,485 | $828,307 |
| Chief Executive Officer | ||||||||
| Kirk Shepard | 463,500 | 0 | 0 | 193,500 | 0 | 0 | 20,318 | 677,318 |
| Chief Medical Officer | ||||||||
| Stephan Toutain | 463,500 | 0 | 0 | 193,500 | 0 | 0 | 16,629 | 673,629 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Frank Bedu-Addo | $828,307 | $2,263,569 | — | ↓ −1,435,262 |
| Kirk Shepard | 677,318 | 1,325,596 | — | ↓ −648,278 |
| Stephan Toutain | 673,629 | 939,788 | — | ↓ −266,159 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
PDS Biotech's compensation program is designed to attract and retain superior talent by aligning executive interests with long-term shareholder value creation through the advancement of its drug pipeline. Because traditional financial metrics are inappropriate for a clinical-stage biotech, the company focuses on R&D achievements, clinical trial progress, regulatory milestones, and business initiatives rather than product sales or profits.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Frank Bedu-Addo | OPTION | 2025-06-12 | — | — | 150,000 | — | $193,500 |
| Kirk Shepard | OPTION | 2025-06-12 | — | — | 150,000 | — | 193,500 |
| Stephan Toutain | OPTION | 2025-06-12 | — | — | 150,000 | — | 193,500 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Frank Bedu-Addo | $0 | $0 | $193,500 | 0.0% |
| Kirk Shepard | 0 | 0 | 193,500 | 0.0% |
| Stephan Toutain | 0 | 0 | 193,500 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Frank Bedu-Addo | Option | 3,594 | 6.28 | — |
| Frank Bedu-Addo | Option | 97,381 | 11.61 | — |
| Kirk Shepard | RSU | 100,000 | — | 76,980 |
| Stephan Toutain | RSU | 100,000 | — | 76,980 |
| Kirk Shepard | Option | 102,877 | 4.49 | — |
| Stephan Toutain | Option | 116,575 | 3.61 | — |
| Frank Bedu-Addo | Option | 150,000 | 1.79 | — |
| Kirk Shepard | Option | 150,000 | 1.79 | — |
| Stephan Toutain | Option | 150,000 | 1.79 | — |
| Frank Bedu-Addo | Option | 161,918 | 5.87 | — |
| Frank Bedu-Addo | RSU | 300,000 | — | 230,940 |
Director compensation
No director compensation table is on file for fiscal year 2025.
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 18,500 / 15,000 / 8,000 |
| Stock ownership guideline | — |
Peer group, and who names PDS Biotechnology as a peer
Companies that benchmark against PDSB
1 company names PDSB as a compensation peer
- Passage BIO, Inc.PASGFY2025
- SELLAS Life Sciences Group, Inc.SLSFY2025
Each company listed discloses PDSB in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PDSB in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PDS Biotechnology Corp | 2025 | Frank Bedu-Addo | $615,322 | $0 | $193,500 | $0 | $828,307 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (9 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Frank Bedu-Addo. DEF 14A, filed 2026-06-26. Section “Executive Compensation”. As printed: 828,307. View filing ↗
- Section 01, Kirk Shepard. DEF 14A, filed 2026-06-26. Section “Executive Compensation”. As printed: 677,318. View filing ↗
- Section 01, Stephan Toutain. DEF 14A, filed 2026-06-26. Section “Executive Compensation”. As printed: 673,629. View filing ↗
- Section 03, Frank Bedu-Addo OPTION. DEF 14A, filed 2026-06-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kirk Shepard OPTION. DEF 14A, filed 2026-06-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Stephan Toutain OPTION. DEF 14A, filed 2026-06-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- PDS Biotechnology Corp (subject), Section 10b CEO total. DEF 14A, filed 2026-06-26. CEO total compensation as printed in PDS Biotechnology Corp's own proxy. As printed: 828,307. View filing ↗